The evolving epidemiology of nasopharyngeal carcinoma
Background: The epidemiology of nasopharyngeal carcinoma (NPC) has long been a
source of fascination due to the malignancy's striking geographic distribution, the …
source of fascination due to the malignancy's striking geographic distribution, the …
[HTML][HTML] The association between the pan-immune-inflammation value and cancer prognosis: a systematic review and meta-analysis
Simple Summary Growing evidence indicates that blood-count-based compound scores
could be used as prognostic biomarkers in cancer as reflectors of uncontrolled inflammation …
could be used as prognostic biomarkers in cancer as reflectors of uncontrolled inflammation …
[HTML][HTML] The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?
Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …
EASL clinical practice guidelines: liver transplantation
European Association for The Study of the Liver - Journal of hepatology, 2016 - Elsevier
The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …
Post-transplantation lymphoproliferative disorders in adults
D Dierickx, TM Habermann - New England Journal of Medicine, 2018 - Mass Medical Soc
Post-Transplantation Lymphoproliferative Disorders Solid-organ and hematopoietic stem-
cell transplants are widely used for various life-threatening medical disorders. Prophylaxis …
cell transplants are widely used for various life-threatening medical disorders. Prophylaxis …
[HTML][HTML] Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy
M Canning, G Guo, M Yu, C Myint… - Frontiers in cell and …, 2019 - frontiersin.org
Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …
Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression”
MB Roberts, JA Fishman - Clinical Infectious Diseases, 2021 - academic.oup.com
Successful solid organ transplantation reflects meticulous attention to the details of
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …
[HTML][HTML] Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Abstract Background Checkpoint inhibitors (CPIs) have revolutionized the treatment of
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …
cancer, but their use remains limited by off-target inflammatory and immune-related adverse …
Epidemiology and etiology of leukemia and lymphoma
JAB Bispo, PS Pinheiro… - Cold Spring …, 2020 - perspectivesinmedicine.cshlp.org
Available evidence suggests that the incidence of leukemia and lymphoma tends to be
higher in highly developed regions of the world and among Whites in the United States …
higher in highly developed regions of the world and among Whites in the United States …
[HTML][HTML] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of oncology, 2020 - Elsevier
Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …